查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1473765

透析器市場- 按類型（高通量、低通量）、按材料（合成、纖維素基）、按用途（一次性、可重複使用）、按最終用途（中心、家庭透析） - 全球預測， 2024 年- 2032

Dialyzers Market - By Type (High-flux, Low-flux), By Material (Synthetic, Cellulose-based), By Usage (Disposable, Reusable), By End-use (In-center, Home Dialysis) - Global Forecast, 2024 - 2032
出版日期: | 出版商: Global Market Insights Inc. | 英文 130 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

在醫療基礎設施投資增加和人口老化的推動下，透析器市場規模預計在 2024 年至 2032 年期間將以 7% 的複合年成長率成長。與生活方式相關的危險因素的增加正在推動對腎臟替代治療的需求不斷成長以及血液透析中心和醫院的快速擴張。

全球慢性腎臟病（CKD）盛行率的不斷上升是該產業成長的另一個重要驅動力。根據國家醫學圖書館的數據，慢性腎臟病影響全球 10% 以上的人口，超過 8 億人。人口老化以及糖尿病和高血壓發病率上升等因素導致需要透析治療的慢性腎臟病患者數量激增。不斷成長的患者群體需要採用透析器來促進腎臟替代治療並改善患者的治療結果。

此外，透析技術的進步，例如高效透析器和改進的生物相容性材料的開發，正在推動市場成長。這些技術創新能夠在血液透析過程中更有效地去除血液中的廢物和多餘液體，從而提高治療效果和患者舒適度。

透析器市場根據類型、材料、用途、最終用途和地區進行分類。

預計到2032 年，低通量透析器類型細分市場的行業規模將以6.6% 的複合年成長率成長。的血液透析過程中廣泛使用。這些透析器也為血液透析治療提供了經濟高效的解決方案，推動了它們在全球醫療機構中的採用。

按材料細分，從2024 年到2032 年，合成透析器市場預計將以7.1% 的複合年成長率擴張。性材料製成的合成透析器具有卓越的性能和生物相容性。這些透析器也因其出色的清除率、降低的血液凝固風險以及與現代透析機的兼容性而成為全球血液透析中心和醫院的首選

受中國、印度和日本慢性腎臟病率不斷上升、醫療基礎設施不斷發展以及醫療支出不斷增加的推動，亞太地區透析器產業預計到 2032 年複合年成長率將達到 8.1%。不斷擴大的患者群體，加上政府改善醫療保健服務機會的舉措，正在推動該地區的市場成長。此外，透析技術的進步和主要市場參與者增加投資將有助於區域產品的吸收。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

  • 產業生態系統分析
  • 產業影響力
    • 成長動力
      • 全球慢性腎臟病盛行率不斷上升
      • 透析器技術的技術進步
      • 對居家透析療法的需求不斷成長
    • 產業陷阱與挑戰
      • 治療費用高
      • 與透析治療相關的併發症的風險
  • 成長潛力分析
  • 監管環境
  • 技術景觀
  • 波特的分析
  • PESTEL分析
  • 定價分析
  • 未來市場趨勢
  • 缺口分析

第 4 章：競爭格局

  • 介紹
  • 公司矩陣分析
  • 公司市佔率分析
  • 競爭定位矩陣
  • 戰略儀表板

第 5 章：市場估計與預測：按類型，2018 - 2032

  • 主要趨勢
  • 高通量透析器
  • 低通量透析器

第 6 章：市場估計與預測：按材料分類，2018 年 - 2032 年

  • 主要趨勢
  • 合成的
  • 纖維素基

第 7 章：市場估計與預測：按用途分類，2018 年 - 2032 年

  • 主要趨勢
  • 一次性的
  • 可重複使用的

第 8 章：市場估計與預測：按最終用途，2018 - 2032 年

  • 主要趨勢
  • 中心
  • 居家透析

第 9 章：市場估計與預測：按地區分類，2018 年 - 2032 年

  • 主要趨勢
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 歐洲其他地區
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
    • 亞太地區其他地區
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 拉丁美洲其他地區
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 中東和非洲其他地區

第 10 章：公司簡介

  • Allmed Medical Care Holdings Limited.
  • Asahi Kasei Medical Co., Ltd.
  • B. Braun Melsungen AG
  • Baxter International Inc.
  • China Chengdu Wesley Biotech Co.
  • Dialifegroup
  • Farmasol
  • Fresenius SE & Co. KGaA
  • Kawasumi Laboratories Inc.
  • Medica Group
  • Medivators, Inc.
  • Medtronic plc
  • Nikkiso Co., Ltd
簡介目錄
Product Code: 4684

Dialyzers Market size is expected to grow at 7% CAGR during 2024-2032, driven by the rising investments in healthcare infrastructure, and aging population. The rise in lifestyle-related risk factors is driving the growing demand for renal replacement therapy and rapid expansion of hemodialysis centers and hospitals.

The increasing prevalence of chronic kidney diseases (CKD) worldwide is another significant driver for the industry growth. According to National Library of Medicine, chronic kidney disease impacts over 10% of the global population, exceeding 800 million individuals. Factors, such as aging population along with the rising incidence of diabetes and hypertension have led to a surge in the number of CKD patients requiring dialysis treatment. This growing patient pool necessitates the adoption of dialyzers to facilitate renal replacement therapy and improve patient outcomes.

Additionally, advancements in dialysis technology, such as the development of high-efficiency dialyzers and improved biocompatible materials, are driving the market growth. These technological innovations enable more efficient removal of waste products and excess fluids from the blood during hemodialysis procedures for enhancing treatment efficacy and patient comfort.

The dialyzers market is classified based on type, material, usage, end-use and region.

The industry size from the low-flux dialyzers type segment is expected to grow at 6.6% CAGR till 2032. This is due to their wide usage in hemodialysis procedures for patients with end-stage renal disease (ESRD) due to their ability to effectively remove waste products and excess fluids from the blood. These dialyzers also offer a cost-effective and efficient solution for hemodialysis treatment, driving their adoption in healthcare facilities worldwide.

By material segmentation, the synthetic dialyzers market is poised to expand at 7.1% CAGR from 2024 to 2032. Synthetic dialyzers, made from biocompatible materials like polysulfone or polyethersulfone membranes, offer superior performance and biocompatibility compared to traditional cellulose-based dialyzers. These dialyzers are also preferred in hemodialysis centers and hospitals globally for their excellent clearance rates, reduced risk of blood clotting, and compatibility with modern dialysis machines

Asia Pacific dialyzers industry is set to gain traction at 8.1% CAGR up to 2032, driven by the increasing prevalence of chronic kidney diseases, growing healthcare infrastructure, and rising healthcare expenditure in China, India, and Japan. The expanding patient pool, coupled with government initiatives to improve access to healthcare services are fueling the market growth in the region. Additionally, advancements in dialysis technology and increasing investments by key market players will contribute to the regional product uptake.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definitions
  • 1.2 Base estimates & calculations
  • 1.3 Data collection
  • 1.4 Forecast parameters
  • 1.5 Data validation
  • 1.6 Data sources
    • 1.6.1 Primary
    • 1.6.2 Secondary
      • 1.6.2.1 Paid sources
      • 1.6.2.2 Unpaid sources

Chapter 2 Executive Summary

  • 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Increasing prevalence of chronic kidney diseases globally
      • 3.2.1.2 Technological advancements in dialyzer technology
      • 3.2.1.3 Rising demand for home dialysis therapies
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 High treatment cost
      • 3.2.2.2 Risk of complications associated with dialysis treatments
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Technological landscape
  • 3.6 Porter's analysis
    • 3.6.1 Supplier power
    • 3.6.2 Buyer power
    • 3.6.3 Threat of new entrants
    • 3.6.4 Threat of substitutes
    • 3.6.5 Industry rivalry
  • 3.7 PESTEL analysis
  • 3.8 Pricing analysis
  • 3.9 Future market trends
  • 3.10 Gap analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company matrix analysis
  • 4.3 Company market share analysis
  • 4.4 Competitive positioning matrix
  • 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2018 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 High-flux dialyzers
  • 5.3 Low-flux dialyzers

Chapter 6 Market Estimates and Forecast, By Material, 2018 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Synthetic
  • 6.3 Cellulose-based

Chapter 7 Market Estimates and Forecast, By Usage, 2018 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Disposable
  • 7.3 Reusable

Chapter 8 Market Estimates and Forecast, By End-Use, 2018 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 In-center
  • 8.3 Home dialysis

Chapter 9 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

  • 9.1 Key trends
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Spain
    • 9.3.5 Italy
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 Japan
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 South Korea
    • 9.4.6 Rest of Asia Pacific
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Argentina
    • 9.5.4 Rest of Latin America
  • 9.6 Middle East and Africa
    • 9.6.1 South Africa
    • 9.6.2 Saudi Arabia
    • 9.6.3 UAE
    • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

  • 10.1 Allmed Medical Care Holdings Limited.
  • 10.2 Asahi Kasei Medical Co., Ltd.
  • 10.3 B. Braun Melsungen AG
  • 10.4 Baxter International Inc.
  • 10.5 China Chengdu Wesley Biotech Co.
  • 10.6 Dialifegroup
  • 10.7 Farmasol
  • 10.8 Fresenius SE & Co. KGaA
  • 10.9 Kawasumi Laboratories Inc.
  • 10.10 Medica Group
  • 10.11 Medivators, Inc.
  • 10.12 Medtronic plc
  • 10.13 Nikkiso Co., Ltd